2-Ethylhexanoic Acid

2-Ethylhexanoic Acid

SCHEMBL19127098

CCCCC(CC)C(=O)O.O=C(O)O.[Cu].[Cu]

nearest known ligand 0.91

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of 2-Ethylhexanoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 7/20 0.91
▸ MAPK1 P28482 2/20 0.91
▸ CA1 P00915 4/20 0.59
▸ SLC1A2 P43004 3/20 0.57
▸ SLC1A1 P43005 3/20 0.57
▸ SLC1A3 P43003 2/20 0.57
▸ CHRM1 P11229 1/20 0.52
▸ AKR1A1 P14550 1/20 0.52
▸ CHRM3 P20309 1/20 0.52
▸ HTR2A P28223 1/20 0.52
▸ HTR2C P28335 1/20 0.52
▸ ADRA1A P35348 1/20 0.52
▸ HRH1 P35367 1/20 0.52
▸ DRD3 P35462 1/20 0.52
▸ SLC6A3 Q01959 1/20 0.52
▸ HDAC1 Q13547 1/20 0.52
▸ HDAC2 Q92769 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ GRIK1 P39086 2/20 0.50
▸ GRIK2 Q13002 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Ethylhexanoic Acid SCHEMBL15390846 0.98 CA2 (0.95) CA2MAPK1CA1SLC1A2SLC1A1
2-Ethylhexanoic Acid SCHEMBL133703 0.98 CA2 (0.95) CA2MAPK1CA1SLC1A2SLC1A1
2-Ethylhexanoic Acid SCHEMBL28232467 0.98 CA2 (0.95) CA2MAPK1CA1SLC1A2SLC1A1
2-Ethylhexanoic Acid SCHEMBL29627551 0.98 CA2 (0.95) CA2MAPK1CA1SLC1A2SLC1A1
2-Ethylhexanoic Acid SCHEMBL27844757 0.95 CA2 (0.91) CA2MAPK1CA1SLC1A2SLC1A1
2-Ethylhexanoic Acid SCHEMBL27872148 0.95 CA2 (0.91) CA2MAPK1CA1SLC1A2SLC1A1
2-Ethylhexanoic Acid SCHEMBL9737644 0.95 CA2 (0.91) CA2MAPK1CA1SLC1A2SLC1A1
2-Ethylhexanoic Acid SCHEMBL7156446 0.95 CA2 (0.91) CA2MAPK1CA1SLC1A2SLC1A1
2-Ethylhexanoic Acid SCHEMBL5695779 0.95 CA2 (1.00) CA2MAPK1CA1SLC1A2SLC1A1
2-Ethylhexanoic Acid SCHEMBL5512393 0.95 CA2 (1.00) CA2MAPK1CA1SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230226807-A1 Polymer Composites and Methods of Making the Same TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2023-07-20 — — US disclosed
WO-2021226424-A1 POLYMER COMPOSITES AND METHODS OF MAKING THE SAME TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2021-11-11 — — WO disclosed
EP-3436537-B1 ANAEROBICALLY CURABLE (METH)ACRYLATE COMPOSITIONS Henkel IP & Holding GmbH (DE) 2021-09-29 — — EP disclosed
US-11111416-B2 Anaerobically curable (meth)acrylate compositions Henkel IP & Holding GmbH (DE) 2021-09-07 — — US disclosed
EP-3402855-B1 CURE OF ANAEROBIC COMPOSITIONS Henkel IP & Holding GmbH (DE) 2021-07-14 — — EP disclosed
WO-2020229096-A1 METHOD FOR BONDING THREE-DIMENSIONAL ARTICLES MADE BY ADDITIVE MANUFACTURING Henkel IP & Holding GmbH (DE) 2020-11-19 — — WO disclosed
US-10414948-B2 Cure of anaerobic compositions Henkel IP & Holding GmbH (DE) 2019-09-17 — — US disclosed
EP-3436537-A1 ANAEROBICALLY CURABLE (METH)ACRYLATE COMPOSITIONS Henkel IP & Holding GmbH (DE) 2019-02-06 — — EP disclosed
US-20190031921-A1 ANAEROBICALLY CURABLE (METH)ACRYLATE COMPOSITIONS HENKEL AG & CO. KGAA (DE) 2019-01-31 — — US disclosed
EP-3402855-A1 CURE OF ANAEROBIC COMPOSITIONS Henkel IP & Holding GmbH (DE) 2018-11-21 — — EP disclosed
US-20180320027-A1 CURE OF ANAEROBIC COMPOSITIONS HENKEL AG & CO. KGAA (DE) 2018-11-08 — — US disclosed
WO-2017168001-A1 ANAEROBICALLY CURABLE (METH)ACRYLATE COMPOSITIONS Henkel IP & Holding GmbH (DE) 2017-10-05 — — WO disclosed
WO-2017121824-A1 CURE OF ANAEROBIC COMPOSITIONS Henkel IP & Holding GmbH (DE) 2017-07-20 — — WO disclosed
Send feedback